Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Carboplatin × NET × Clear all

Phase

Status

Completed 3 Not yet recruiting 1 Enrolling by invitation 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 113 Breast 46 Gynecologic 37 Gastrointestinal 26 Head & Neck 22 Genitourinary 22 CNS 12 Sarcoma 6 Other solid neoplasm 6 Lymphoid 6 Dermatologic 5 Endocrine 3 Tumor-Agnostic 2 Other hematologic neoplasm 2 NET 1 Myeloid 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 13 Magnetic Resonance Spectroscopy 6 Specimen Handling 5 Nivolumab 5 cabozantinib 4 pembrolizumab 3 Octreotide 3 Ipilimumab 3 Everolimus 3 amino-acid, glucose, and electrolyte solution 2 X-Rays 2 Temozolomide 2 Phantoms, Imaging 2 Lutetium-177 2 3-aminopyridine-2-carboxaldehyde thiosemicarbazone 2 177Lu-octreotide, DOTA(0)-Tyr(3)- 2 toripalimab 1 tislelizumab 1 peposertib 1 pazopanib 1 pasireotide 1 lenvatinib 1 entrectinib 1 copper dotatate CU-64 1 avelumab 1 abemaciclib 1 Salts 1 Receptor-Like Protein Tyrosine Phosphatases, Class 2 1 Random Allocation 1 Radionuclide Imaging 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06232564 2026-01-14

PELICAN

Imperial College London

Phase 2 Active not recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡